2013
DOI: 10.1001/jamaoto.2013.4185
|View full text |Cite
|
Sign up to set email alerts
|

Use ofSLC26A4Mutation Testing for Unilateral Enlargement of the Vestibular Aqueduct

Abstract: Unilateral EVA can be associated with all possible SLC26A4 genotype results. The distinct combination of prognoses and recurrence probability associated with each genotype supports the clinical use of testing for SLC26A4 mutations in subjects with unilateral EVA.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
24
0
1

Year Published

2014
2014
2019
2019

Publication Types

Select...
6
1

Relationship

3
4

Authors

Journals

citations
Cited by 28 publications
(26 citation statements)
references
References 20 publications
1
24
0
1
Order By: Relevance
“…We previously reported two unilateral EVA subjects in the NIH cohort with two mutant alleles of SLC26A4 , leading us to propose an expansion of the indications for SLC26A4 testing to include unilateral EVA 8. In our current study, two (18%) of 11 NIH M1 subjects carrying the CEVA haplotype had unilateral hearing loss and EVA (table 3).…”
Section: Discussionsupporting
confidence: 51%
“…We previously reported two unilateral EVA subjects in the NIH cohort with two mutant alleles of SLC26A4 , leading us to propose an expansion of the indications for SLC26A4 testing to include unilateral EVA 8. In our current study, two (18%) of 11 NIH M1 subjects carrying the CEVA haplotype had unilateral hearing loss and EVA (table 3).…”
Section: Discussionsupporting
confidence: 51%
“…This could imply that monoallelic SLC26A4 mutations may play a role in hearing impairment but are not the only cause of hearing loss in the IEVA individuals. A study on unilateral EVA subjects supports this because only 8.3% had two mutant alleles, 16.7% had one mutant allele, and 75% had no mutant alleles in the SLC26A4 gene …”
Section: Discussionmentioning
confidence: 91%
“…Subjects, methods, and their description are essentially as reported . Our study was approved by the Combined Neuroscience Institutional Review Board, National Institutes of Health (NIH), Bethesda, Maryland.…”
Section: Methodsmentioning
confidence: 99%
“…Subjects were evaluated at the NIH Clinical Center as previously described . We relied upon records from outside healthcare providers for subjects who did not come to the NIH Clinical Center.…”
Section: Methodsmentioning
confidence: 99%